Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CFTR | P13569 | 1/20 | 0.41 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31132270 | 1.00 | RAB9A (0.49) | RAB9AGAANPC1PKMLTA4H | |
| SCHEMBL26026914 | 0.83 | RAB9A (0.47) | RAB9AGAANPC1PKMLTA4H | |
| SCHEMBL7479351 | 0.81 | RAB9A (0.49) | RAB9AGAANPC1PKMLTA4H | |
| SCHEMBL23128474 | 0.80 | RAB9A (0.42) | RAB9AGAANPC1PKMLTA4H | |
| SCHEMBL2103950 | 0.78 | — | — | |
| SCHEMBL1581280 | 0.75 | CA12 (0.41) | RAB9AGAANPC1CA12CA1 | |
| SCHEMBL1150196 | 0.75 | KDM4E (0.51) | RAB9AGAACA12CA1CA2 | |
| SCHEMBL31459126 | 0.75 | BCL6 (0.58) | GAAKDM4E | |
| SCHEMBL11051 | 0.74 | CA12 (0.53) | RAB9AGAACA12CA1CA2 | |
| SCHEMBL16371883 | 0.74 | CA12 (0.53) | RAB9AGAACA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117300060-A | Lost foam casting process for machine tool wear-resistant accessory | 浙江浦江精宇铸造有限公司 | 2023-12-29 | — | — | CN | claimed |
| CN-117300060-A | Lost foam casting process for machine tool wear-resistant accessory | 浙江浦江精宇铸造有限公司 | 2023-12-29 | — | — | CN | disclosed |
| CN-113968864-B | Cu based on zinc porphyrin axial coordination regulation + Fluorescent probe, preparation method and application | 浙大城市学院 | 2023-04-07 | — | — | CN | disclosed |
| CN-114036878-A | Dual neuromorphic device based on charge trapping effect and electric double-layer effect and preparation method thereof | 电子科技大学长三角研究院(湖州) | 2022-02-11 | — | — | CN | disclosed |
| CN-113968864-A | Cu based on zinc porphyrin axial coordination regulation+Fluorescent probe, preparation method and application | 浙大城市学院 | 2022-01-25 | — | — | CN | disclosed |
| EP-2010516-B1 | TRISUBSTITUTED 1,2,4-TRIAZOLES | JANSSEN PHARMACEUTICA NV (BE) | 2014-07-02 | — | — | EP | disclosed |
| CN-101472911-B | Trisubstituted 1,2,4-triazoles | JANSSEN PHARMACEUTICA NV | 2014-07-02 | — | — | CN | disclosed |
| US-8143419-B2 | Trisubstituted 1,2,4-triazoles | JANSSEN PHARMACEUTICA N. V. (BE) | 2012-03-27 | — | — | US | disclosed |
| US-20090253691-A1 | TRISUBSTITUTED 1,2,4-TRIAZOLES | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-10-08 | — | — | US | disclosed |
| CN-101472911-A | Trisubstituted 1,2,4-triazoles | JANSSEN PHARMACEUTICA NV (BE) | 2009-07-01 | — | — | CN | disclosed |
| EP-2010516-A1 | TRISUBSTITUTED 1,2,4-TRIAZOLES | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-01-07 | — | — | EP | disclosed |
| US-7351835-B2 | Organic molecular cataylst having binaphthol skeleton and processes for producing the same and application thereof | MEIJI SEIKA KAISHA LTD. (JP) | 2008-04-01 | — | — | US | disclosed |
| WO-2007118903-A1 | TRISUBSTITUTED 1,2,4-TRIAZOLES | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-25 | — | — | WO | disclosed |
| US-20060009646-A1 | Novel organic molecular catalyst having binaphthol skeketon and processes for producing the same and application thereof | MEIJI SEIKA KAISHA LTD. (JP) | 2006-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060009646-A1 | Novel organic molecular catalyst having binaphthol skeketon and processes for producing the same and application thereof | SQLE, OGDH, CYP17A1 | RAB9A 4007/4885GAA 631/4885NPC1 3324/4885 |
| US-20090253691-A1 | TRISUBSTITUTED 1,2,4-TRIAZOLES | CHRNA1, CHRNA5, CHRNA3 | RAB9A 1835/4885GAA 3210/4885NPC1 2263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.